Commentary on the clinical trial reported by: Tewari KS, Sill M, Long III HJ, et al. Incorporation of bevacizumab in the treatment of recurrent and metastatic cervical cancer: a phase III randomized trial of the Gynecologic Oncology Group. J Clin Oncol 2013;(suppl; abstr 3)

Michael L. Friedlander


One of the highlights of the recent ASCO meeting was the presentation of the results of GOG 240 by Tewari on behalf of his co-investigators in a plenary session (1). This was a positive trial which reported a significant increase in overall survival (OS) of women with metastatic/recurrent cervical cancer who were treated with bevacizumab in combination with chemotherapy. This is likely to change the standard of care of women with recurrent/metastatic cervical cancer in well-resourced regions of the world in particular and deserves review and detailed discussion.